Fri Oct 24 20:46:31 SAST 2014
Connie returns to save troubled Generations

Connie Ferguson has confirmed that she will be returning to Generations after weeks of dodging circu.

Anti-cancer drug for women weakens bone density

By Sapa-AFP | Feb 07, 2012 | COMMENTS [ 0 ]

A drug tipped for widespread use to prevent breast cancer in post-menopausal women also accelerates loss of bone density, thus potentially boosting the risk of fractures, said a published study.

Exemestane -- brand name Aromasin -- is part of a drug class called aromatase inhibitors, which lower levels of the oestrogen that some breast cancers need in order to grow.

Canadian bone specialists took a look at a group of patients who had taken part in a study into the effectiveness of exemestane among 4,500 healthy women with a worrying family history of breast cancer.

Overall, the big study showed that the drug was highly effective, reducing the risk of breast cancer by almost two-thirds.

The bone sub-study looked at 351 women who had been taking either exemestane or a dummy lookalike pill and whose bone density was measured with hi-tech scanners.

After two years, women taking exemestane had a high loss of bone density at a common fracture point in the wrist called the distal radius, and also at the lower end of the tibia, compared with their counterparts on placebo.

The exemestane users also had an eight-percent decline in the thickness of cortical bone, which comprises the protective outer shell of the bones.

That finding in particular is worrying because nearly four out of every five fractures in old age occur in cortical bone. These accidents are a huge source of disability.

"Women considering exemestane for the primary prevention of breast cancer should weigh their individual risks and benefits," says the study, headed by Angela Cheung of the University Health Network in Toronto.

"For women taking exemestane, regular bone monitoring plus adequate calcium and vitamin D supplementation are important."

The paper is published online by the journal The Lancet Oncology.

COMMENTS [ 0 ]

Login OR Join up TO COMMENT